PD 0325901

Grouped product items
Size	Price	Qty
10mg	$125.00
25mg	$250.00

Catalog Number : 3911091

description

PD 0325901 is a potent and selective MEK1 and MEK2 inhibitor. It is reported to inhibit cell proliferation and arrest cell cycle at the G0/G1 phase of thyroid cancer cells. PD 0325901 can be used with CHIR99021 to reprogram somatic cells into iPS cells and promote cell self-renewal. Studies have shown that in comparison to the CI-1040 MEK inhibitor that PD 0325901 has a greater potency of inhibition, longer duration, greater solubility, improved bioavailability, and increased metabolic stability.

Additional Information

Applications:	FA
Synonyms:	PD-0325901, ZINC03938683, NCGC00189075-01, (R)-N-(2,3-Dihydroxypropoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide
Formulation:	Crystalline solid
Chemical Name:	N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide
Molecular Formula:	C₁₆H₁₄F₃IN₂O₄
Molecular Weight:	482.2
CAS Number	391210-10-9
Purity:	≥98%
Storage Conditions:	Product should be kept at -20°C.
References:	Sebolt-Leopold, J. S., Merriman, R., Omer, C., Tecle, H., Bridges, A., Klohs, W., ... & Leopold, W. R. (2004). The biological profile of PD 0325901: A second generation analog of CI-1040 with improved pharmaceutical potential. Cancer Research, 64(7 Supplement), 925-925. Haura, E. B., Ricart, A. D., Larson, T. G., Stella, P. J., Bazhenova, L., Miller, V. A., ... & Gadgeel, S. M. (2010). A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non–small cell lung cancer. Clinical Cancer Research, 16(8), 2450-2457. Leyton, J., Smith, G., Lees, M., Perumal, M., Aigbirhio, F. I., Golovko, O., ... & Aboagye, E. O. (2008). Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901. Molecular cancer therapeutics, 7(9), 3112-3121.